Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 80 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Yang G.

United States

USD 80 /hr

Experienced Drug Discovery Scientist | Expert in Oncology & Inflammatory Diseases | Project Management

Profile Summary

Experienced drug discovery scientist with a focus on oncology and inflammatory disease therapeutics, skilled in leading cross-functional teams and advancing complex preclinical programs. --Oncology & Inflammatory Disease Drug Discovery: 10+ years in preclinical discovery, specializing in small-molecule inhibitors of novel modalities targeting oncogenic and inflammatory pathways, progressing projects from target selection to IND-enabling studies. --Assay Development & Mechanistic Biology: Expert in developing high-throughput biochemical and cell-based functional & phenotypic assays to validate therapeutic targets. --Cross-Functional Team Leadership: Proven leader in coordinating cross-disciplinary teams across biology, chemistry, and pharmacology, delivering project milestones through effective timeline and goal alignment. --Project & Program Management: Skilled in managing complex projects, including CRO oversight, resource allocation, and workflow optimization, ensuring successful outcomes in fast-paced environments. --Scientific Communication & Documentation: Strong communicator with a track record of translating scientific insights into clear presentations and reports, with 20+ publications and technical documents, including patent applications. (Link to Google Scholar: https://scholar.google.com/citations?user=-juQkG8AAAAJ&hl=en)

Subject Matter Expertise

• ★ Drug Development
• ★ Cancer Research
• ☆ Biochemistry
• ☆ Biochemical Assays
• ☆ Molecular Biology
• ☆ Biomarkers
• ☆ Genetics
• ☆ Omics
• ☆ Transcriptomics
• ☆ Epigenetics
• ☆ Next Generation Sequencing (NGS)
• ☆ Cell Biology
• ☆ Cell-Based Assays
• ☆ Cell Signaling Pathways
• ☆ Drug Discovery
• ☆ High Throughput Screening (HTS)
• ☆ Drug Target Identification
• ☆ Hit-to-Lead & Lead Optimization
• ☆ Phenotypic Assays
• ☆ High Content Screening/Imaging
• ☆ Structure-Activity Relationship (SAR) Studies
• ☆ Small Molecule Drug Development
• ☆ Preclinical ADME/PK/PD
• ☆ Drug-Drug Interactions
• ☆ Preclinical Research
• ☆ Preclinical Pharmacology
• ☆ In vivo Preclinical Toxicology
• ☆ Pharmaceutical Regulatory Affairs
• ☆ Drug Efficacy Testing
• ☆ Bioavailability
• ☆ Pediatric Medicine
• ☆ Oncology
• ☆ Chemotherapy
• ☆ Pediatric Oncology
• ☆ Immunotherapy
• ☆ Inflammation
• ☆ Cancer Biology
• ☆ Carcinogenesis
• ☆ Pediatric Hematology-Oncology
• ☆ Hypothesis
• ☆ Peer Review
• ☆ Research Methodology
• ☆ Fact Checking
• ☆ Literature Search
• ☆ Project Management

Services

• Writing
• Research
• Consulting

Writing Technical Writing, General Proofreading & Editing, Translation

Research User Research, Feasibility Study, Technology Scouting, Fact Checking, Gap Analysis, Scientific and Technical Research, Systematic Literature Review, Secondary Data Collection

Consulting Business Strategy Consulting, Operations Consulting, Scientific and Technical Consulting

Work Experience

Team Lead, Drug Discovery

Talus Bioscience

June 2022 - July 2024

Senior Scientist

Exo Therapeutics

June 2021 - December 2022

Scientist I | Project Lead

Dana Farber Cancer Institute

April 2019 - June 2021

Research Fellow

Pediatric Oncology Department | Dana-Farber Cancer Institute

April 2014 - April 2019

Education

Biological Chemistry

University of Pittsburgh

September 2008 - April 2014

Certifications

• Project Management Principles and Practices

  University of California, Irvine

  https://coursera.org/share/0e1b477c561635795c421611f7df3edf

  January 2024 - Present

Publications

JOURNAL ARTICLE

Federation, Alexander Joel, Gao, Yang, McEllin, Brian, Gatbonton-Schwager, Tonibelle, Gutierrez, Andrea, Robbins, Julia, Hueffmeier, Bodhi, Broderick, Erin, Canzani, Daniele, Fondrie, William, et al.(2024). Profiling the DNA regulome to discover direct inhibitors of the brachyury transcription factor. Cancer Research. 84. (6\_Supplement). p. 3225--3225. AACR

Gao, Yang, Jiang, Baishan, Kim, Hellen, Berberich, Matthew J, Che, Jianwei, Donovan, Katherine A, Hatcher, John M, Huerta, Fidel, Kwiatkowski, Nicholas P, Liu, Yingpeng, et al.(2023). Catalytic degraders effectively address kinase site mutations in EML4-ALK oncogenic fusions. Journal of Medicinal Chemistry. 66. (8). p. 5524--5535. American Chemical Society

Lu, Wenchao, Liu, Yao, Gao, Yang, Geng, Qixiang, Gurbani, Deepak, Li, Lianbo, Ficarro, Scott B, Meyer, Cynthia J, Sinha, Dhiraj, You, Inchul, et al.(2023). Development of a covalent inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1. Journal of Medicinal Chemistry. 66. (5). p. 3356--3371. American Chemical Society

Gao, Yang, Jiang, Baishan, Kim, Hellen, Che, Jianwei, Donovan, Katherine, Hatcher, John, Huerta, Fidel, Kwiatkowski, Nicholas, Liu, Yingpeng, Liuni, Peter, et al.(2023). Catalytic degraders effectively address kinase site mutations in EML-ALK oncogenic fusions. Cancer Research. 83. (7\_Supplement). p. 3426--3426. The American Association for Cancer Research

Gao, Yang, Volegova, Marina, Nasholm, Nicole, Das, Sanjukta, Kwiatkowski, Nicholas, Abraham, Brian J, Zhang, Tinghu, Gray, Nathanael S, Gustafson, Clay, Krajewska, Malgorzata, et al.(2022). Synergistic anti-tumor effect of combining selective CDK7 and BRD4 inhibition in neuroblastoma. Frontiers in Oncology. 11. p. 773186. Frontiers Media SA

Li, Zhengnian, Ishida, Ryosuke, Liu, Yan, Wang, Jinhua, Li, Yina, Gao, Yang, Jiang, Jie, Che, Jianwei, Sheltzer, Jason M, Robers, Matthew B, et al.(2022). Synthesis and Structure--Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. European journal of medicinal chemistry. 238. p. 114433. Elsevier Masson

Fan, Mengyang, Lu, Wenchao, Che, Jianwei, Kwiatkowski, Nicholas P, Gao, Yang, Seo, Hyuk-Soo, Ficarro, Scott B, Gokhale, Prafulla C, Liu, Yao, Geffken, Ezekiel A, et al.(2022). Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling. Elife. 11. p. e78810. eLife Sciences Publications Limited

Jiang, Baishan, Gao, Yang, Che, Jianwei, Lu, Wenchao, Kaltheuner, Ines H, Dries, Ruben, Kalocsay, Marian, Berberich, Matthew J, Jiang, Jie, You, Inchul, et al.(2021). Discovery and resistance mechanism of a selective CDK12 degrader. Nature chemical biology. 17. (6). p. 675--683. Nature Publishing Group US New York

Liu, Yao, Hao, Mingfeng, Leggett, Alan L, Gao, Yang, Ficarro, Scott B, Che, Jianwei, He, Zhixiang, Olson, Calla M, Marto, Jarrod A, Kwiatkowski, Nicholas P, et al.(2020). Discovery of MFH290: a potent and highly selective covalent inhibitor for cyclin-dependent kinase 12/13. Journal of Medicinal Chemistry. 63. (13). p. 6708--6726. American Chemical Society

Jiang, Jie, Jiang, Baishan, He, Zhixiang, Ficarro, Scott B, Che, Jianwei, Marto, Jarrod A, Gao, Yang, Zhang, Tinghu, Gray, Nathanael S(2020). Discovery of covalent MKK4/7 dual inhibitor. Cell Chemical Biology. 27. (12). p. 1553--1560. Elsevier

Kurppa, Kari J, Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H, Xie, Yingtian, Lim, Klothilda, Cejas, Paloma, et al.(2020). Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer cell. 37. (1). p. 104--122. Elsevier

Debruyne, David N, Dries, Ruben, Sengupta, Satyaki, Seruggia, Davide, Gao, Yang, Sharma, Bandana, Huang, Hao, Moreau, Lisa, McLane, Michael, Day, Daniel S, et al.(2019). BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature. 572. (7771). p. 676--680. Nature Publishing Group UK London

Krajewska, Malgorzata, Dries, Ruben, Grassetti, Andrew V, Dust, Sofia, Gao, Yang, Huang, Hao, Sharma, Bandana, Day, Daniel S, Kwiatkowski, Nicholas, Pomaville, Monica, et al.(2019). CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nature communications. 10. (1). p. 1757. Nature Publishing Group UK London

Powell, Chelsea E, Gao, Yang, Tan, Li, Donovan, Katherine A, Nowak, Radosław P, Loehr, Amanda, Bahcall, Magda, Fischer, Eric S, Jänne, Pasi A, George, Rani E, et al.(2018). Chemically induced degradation of anaplastic lymphoma kinase (ALK). Journal of medicinal chemistry. 61. (9). p. 4249--4255. American Chemical Society

Gao, Yang, Zhang, Tinghu, Terai, Hideki, Ficarro, Scott B, Kwiatkowski, Nicholas, Hao, Ming-Feng, Sharma, Bandana, Christensen, Camilla L, Chipumuro, Edmond, Wong, Kwok-kin, et al.(2018). Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors. Cell chemical biology. 25. (2). p. 135--142. Elsevier

Hatcher, John M, Bahcall, Magda, Choi, Hwan Geun, Gao, Yang, Sim, Taebo, George, Rani, Jänne, Pasi A, Gray, Nathanael S(2015). Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation. Journal of medicinal chemistry. 58. (23). p. 9296--9308. American Chemical Society

Gao, Yang, Liang, Yanke, Zhang, Tinghu, Gray, Nathanael S, George, Rani E(2015). Abstract B165: Optimizing selective CDK7 inhibition in MYCN-driven neuroblastoma. Molecular Cancer Therapeutics. 14. (12\_Supplement\_2). p. B165--B165. The American Association for Cancer Research

Gao, Yang, Trevidi, Sumita, Ferris, Robert, Koide, Kazunori(2014). Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer c. Scientific Reports. 4. Nature

Gao, Yang, Osman, Sami, Koide, Kazunori(2014). Total Synthesis and Biological Studies of TMC-205 and Analogues as Anticancer Agents and Activators of SV40 Promoter. ACS Medicinal Chemistry Letters. 5. (8). p. 863--867. American Chemistry Society

Gao, Yang, Koide, Kazunori(2013). Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells. ACS chemical biology. 8. (5). p. 895--900. American Chemical Society

Gao, Yang, Vogt, Andreas, Forsyth, Craig J, Koide, Kazunori(2012). Comparison of splicing factor 3b inhibitors in human cells. Chembiochem: a European journal of chemical biology. 14. (1). p. 49--52.

OTHER

Hatcher, John M, Gray, Nathanael S, Jiang, Baishan, Zhang, Tinghu, Che, Jianwei, Gao, Yang, Jones, Lyn Howard(2023). Potent and selective degraders of alk.

Che, Jianwei, Gray, Nathanael S, Zhang, Tinghu, Jiang, Baishan, Gao, Yang, Kwiatkowski, Nicholas Paul(2022). Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof.

Gray, Nathanael S, Zhang, Tinghu, Liu, Yao, Gao, Yang(2022). Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof.

Gray, Nathanael S, Zhang, Tinghu, Liu, Yao, Gao, Yang(2022). PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASE AND THEIR USES.

Gray, Nathanael S, Zhang, Tinghu, Che, Jianwei, Kwiatkowski, Nicholas Paul, Mengyang, FAN, Lu, Wenchao(2021). Transcriptional enhanced associate doman (tead) transcription factor inhibitors and uses thereof.

Che, Jianwei, Gray, Nathanael S, Zhang, Tinghu, JIANG, Baishan, Gao, Yang, Kwiatkowski, Nicholas Paul(2020). Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof.

Gray, Nathanael S, Zhang, Tinghu, Liu, Yao, Gao, Yang(2020). Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof.

DISSERTATION THESIS

Gao, Yang(2014). REGULATING PRE-MRNA SPLICING AND TRANSCRIPTION USING SMALL MOLECULES FOR CANCER THERAPY.